• Explore /
  • Poster
  • / A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).

A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).

Abstract Video & Slides Poster

Authors

null

Daniel H. Ahn

Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

Daniel H. Ahn , Afsaneh Barzi , Maya Ridinger , Errin Samuelsz , Mark G. Erlander , Tanios S. Bekaii-Saab , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03829410

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4116)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4116

Abstract #

TPS4116

Poster Bd #

108

Abstract Disclosures

Similar Posters

First Author: S. Stintzing

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: Heinz-Josef Lenz